Company Description
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases.
The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers.
It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase.
Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs.
The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017.
Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
| Country | United States |
| IPO Date | Dec 16, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Dr. Alan D. Horsager Ph.D. |
Contact Details
Address: 420 Lexington Avenue New York, New York United States | |
| Website | https://scopusbiopharma.com |
Stock Details
| Ticker Symbol | SCPS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001772028 |
| CUSIP Number | 809171101 |
| ISIN Number | US8091711015 |
| Employer ID | 82-1248020 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alan D. Horsager Ph.D. | President?of?Immuno-Oncology and President & Chief Executive Officer of Duet BioTherapeutics |
| Ira Scott Greenspan | Senior Advisor & Director |
| Robert J. Gibson | Vice Chairman, Secretary & Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 09, 2024 | 1-Z | Filing |
| Jan 19, 2024 | 15-12G | Filing |
| Aug 18, 2023 | 8-K | Current Report |
| Aug 11, 2023 | 8-K | Current Report |
| Aug 11, 2023 | 10-Q | Quarterly Report |
| Jul 21, 2023 | DEF 14A | Filing |
| Jun 28, 2023 | PRER14A | Filing |
| May 12, 2023 | 10-Q | Quarterly Report |
| Apr 28, 2023 | 10-K/A | [Amend] Annual Report |
| Apr 14, 2023 | 10-K | Annual Report |